GLP-1 Medicare Pilot Program: $50 Access Starting July 2026

For years, Medicare beneficiaries watched from the sidelines as GLP-1 medications like Wegovy and Zepbound transformed weight management for millions of Americans. The catch? Medicare couldn’t cover these drugs when prescribed for obesity. That changes on July 1, 2026.

The Centers for Medicare and Medicaid Services (CMS) is launching the Medicare GLP-1 Bridge, a pilot program that marks the first time Medicare will directly cover weight-loss medications. I’ve spent time digging through CMS announcements, manufacturer agreements, and eligibility documents to put together everything you need to know. No fluff, just the facts that matter.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge is a time-limited demonstration program created by CMS under Section 402 authority. It’s designed to test whether providing Medicare beneficiaries access to GLP-1 weight-loss medications at a reduced cost improves health outcomes while keeping spending manageable.

Here’s the backstory. Medicare has been prohibited from covering weight-loss medications since the Part D program was created in 2003. That prohibition stayed in place even as the science around obesity changed dramatically. When GLP-1 drugs showed they could do more than help people shed pounds (reducing heart attacks, improving kidney function, lowering stroke risk), pressure mounted to rethink the policy.

API 400 “This Organization Has Been Disabled”: Fix It in 5 Minutes

The Trump administration struck what it called a “most-favored-nation” deal with Novo Nordisk and Eli Lilly, the two largest GLP-1 manufacturers. The result: the Bridge program, which sidesteps the statutory ban by operating outside the standard Part D system. CMS Administrator Dr. Mehmet Oz put it plainly: “These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost. The Medicare GLP-1 Bridge changes that.”

Originally, the Bridge was set to run just six months (July through December 2026). But in April 2026, CMS announced it would extend the program through December 31, 2027, giving beneficiaries a full 18 months of access. The longer timeline also gives CMS more data to work with as it evaluates a permanent solution.

Which GLP-1 Drugs Are Covered (and Which Aren’t)?

Not every GLP-1 medication made the list. The Bridge program specifically targets drugs FDA-approved for weight reduction, while leaving diabetes medications under regular Part D rules. Here’s the breakdown:

Medication	FDA Approval	Covered Under Regular Part D?	Covered Under GLP-1 Bridge?
Wegovy (semaglutide)	Weight Loss / Cardiovascular Risk	Only for reducing severe cardiovascular risk	Yes – All formulations
Zepbound (tirzepatide)	Weight Loss	No	Yes – KwikPen only
Foundayo (oral semaglutide)	Weight Loss	No	Yes – All formulations
Ozempic / Mounjaro	Type 2 Diabetes	Yes (strictly for Type 2 Diabetes)	No – Use regular Part D

A couple of things stand out here. First, Ozempic isn’t part of the Bridge at all because it remains covered under standard Part D rules for diabetes. If you’re already getting Ozempic covered for type 2 diabetes, nothing changes for you. Second, the manufacturers have hinted that new GLP-1 oral pills could be added mid-2026 if the FDA approves them in time.

Who Qualifies? The Three BMI Tiers Explained

Eligibility for the Bridge program isn’t automatic. Your doctor needs to submit a prior authorization request confirming that you meet one of three clinical tiers. CMS designed this tiered system to prioritize patients with the highest health risks.

Tier	BMI Requirement	Required Health Conditions	Notes
Tier 1	35 or higher	None required	Highest priority. No additional conditions needed.
Tier 2	30 or higher	Heart failure, uncontrolled hypertension, or chronic kidney disease	Must have at least one comorbid condition.
Tier 3	27 or higher	Prediabetes, history of heart attack or stroke, or peripheral artery disease	Lowest BMI threshold but requires diagnosed condition.

Your prescriber needs to document that the medication is being prescribed for weight reduction and maintenance, not just general wellness. CMS will review each prior authorization request through a centralized processor (currently set to be Humana).

What You’ll Actually Pay: Cost Breakdown

The headline number is straightforward: $50 per month for a 30-day supply. But the full financial picture has a few more layers worth understanding.

Manufacturers have agreed to a net price of $245 per monthly supply. You pay $50. CMS handles the rest through the demonstration program’s separate funding structure. Chris Klomp, Director of Medicare at HHS, noted that this approach was designed to make costs “simpler, more predictable, and more consistent.”

But here’s something you should know: that $50 monthly copay does not count toward your regular Part D out-of-pocket maximum. The Bridge operates entirely outside the Part D system, which means those payments don’t get applied to the $2,100 annual cap that took effect in 2025.

Cost Factor	Under GLP-1 Bridge	Under Standard Part D
Monthly medication cost	$50 flat copay	$325-$430 (25-33% coinsurance)
Annual out-of-pocket max	Does not apply	$2,100 cap
Counts toward deductible	No	Yes
Extra Help / LIS subsidies	Not available	Available if you qualify
Manufacturer net price	$245/month (negotiated)	$700-$800/month (typical net)

If you currently receive Extra Help or Low-Income Subsidies (LIS), those protections don’t apply to the Bridge program. Your copay stays at $50 regardless of income level. For some beneficiaries who receive full LIS under Part D, this could actually mean paying more than you would under the standard benefit. It’s worth running the numbers with your plan or a State Health Insurance Assistance Program (SHIP) counselor.

How to Enroll: Step-by-Step

Enrollment doesn’t work like typical Part D sign-up. Since the Bridge is a demonstration program operating outside normal Part D channels, the process has its own workflow. Here’s what you need to do:

Step	Action	What You Need to Know
1	Confirm Part D enrollment	You must be enrolled in a Medicare Part D plan or a Medicare Advantage plan with drug coverage. The Bridge doesn’t replace your plan; it runs alongside it.
2	Schedule a doctor visit	Talk to your primary care physician or endocrinologist. They’ll need to verify your BMI and any qualifying health conditions.
3	Get prior authorization	Your doctor submits a PA request to CMS through the central processor, attesting that you meet one of the three BMI tiers and are being prescribed the drug for weight reduction.
4	Wait for approval	CMS or the central processor reviews your case. Response times haven’t been published yet, but most Part D PA decisions come within 72 hours for urgent requests.
5	Fill your prescription	Take your approval to a participating pharmacy. You pay $50 at the counter. The pharmacy submits the claim to the central processor for reimbursement.

CMS has indicated that beneficiaries don’t need to “apply” to the Bridge program directly. Instead, the process kicks off when your doctor submits the prior authorization request. Once you’re approved, your $50 copay should work at any participating pharmacy.

The Fine Print: 5 Things to Watch Out For

Pilot programs come with quirks. The Bridge has several features that differ from standard Medicare coverage, and some of them could trip you up if you’re not prepared.

1. It runs outside Part D. Even though you need Part D to qualify, the Bridge program is managed separately. Humana is serving as the central claims processor, not your regular Part D insurer. This means your usual pharmacy network might not apply.
2. Payments don’t count toward your out-of-pocket max. The $50 monthly copays won’t accumulate toward the $2,100 annual Part D spending cap. If you take other expensive medications, this separation matters.
3. No Extra Help or LIS. Low-income subsidies that normally reduce Part D costs don’t extend to the Bridge. Everyone pays the same $50, which helps higher-income beneficiaries but may not help those who currently get medications nearly free through LIS.
4. Coverage ends December 31, 2027. This is a time-limited demonstration. After that date, you’ll need Congress to pass permanent legislation (like the Treat and Reduce Obesity Act) or CMS to establish a permanent model to keep coverage going.
5. The BALANCE Model is delayed indefinitely. Originally, the Bridge was supposed to hand off to a permanent BALANCE Model in January 2027. CMS announced in May 2026 that the BALANCE Model for Part D has been delayed with no new start date. The Bridge extension through 2027 fills that gap, but long-term coverage remains uncertain.

What About Medicaid Coverage?

The picture for Medicaid beneficiaries is different and more complicated. Under the GENEROUS model announced in late 2025, state Medicaid programs can opt in to provide lower-priced GLP-1 medications to enrollees. But participation isn’t mandatory. Each state must submit a letter of intent and negotiate its own agreement.

This means coverage will vary significantly depending on where you live. Some states may move quickly to add GLP-1 coverage; others may not participate at all. The net prices for Medicaid programs are confidential, so we don’t yet know what copays state enrollees will face. If you’re dual-eligible (enrolled in both Medicare and Medicaid), your Medicare Bridge eligibility takes precedence for the medications covered under that program.

The Road Ahead: What Happens After 2027?

Long-term coverage hinges on a few moving pieces. The Treat and Reduce Obesity Act (TROA), which has been introduced in multiple sessions of Congress, would permanently remove the statutory ban on weight-loss drug coverage in Medicare. The bill has bipartisan sponsors but hasn’t reached the floor for a vote yet.

Separately, Medicare drug price negotiation under the Inflation Reduction Act has already selected Ozempic and Wegovy for 2027 price setting. CMS must announce the negotiated prices by November 30, 2025, with those prices taking effect January 1, 2027. It’s not yet clear whether the negotiated prices will align with the $245 net price in the Bridge agreement, but the convergence of these two tracks suggests costs should stay lower than list prices either way.

A 2024 analysis published in JAMA Network Open projected that covering GLP-1s for obesity treatment would reach about 3 million Medicare beneficiaries over 10 years, with total drug costs of roughly $65.9 billion. Health care savings from reduced comorbidities were estimated at $18.2 billion, leaving a net increase in spending of $47.7 billion. Whether Congress views that investment as worthwhile may determine what happens when the Bridge ends.